Improved preclinical safety assessment using micro-BAL devices: The potential impact on human discovery and drug attrition

Drug Discovery Today

Volumn 16, Issue 9-10, 2011, Pages 382-397

  Giri, Shibashish ^a   Bader, Augustinus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DRUG METABOLITE; GROWTH FACTOR; MOLECULAR SCAFFOLD;

BIOARTIFICIAL LIVER; BIOCOMPATIBILITY; BIOLOGICAL MODEL; CELL CULTURE; CULTURE TECHNIQUE; DEVICE SAFETY; HUMAN; LIVER TOXICITY; OXYGENATION; REVIEW; STEM CELL;

DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; LIVER, ARTIFICIAL; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS;

EID: 79956044457     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.02.012     Document Type: Review

References (133)

1. M.P. Steven How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
2. J.P. Hughes Principles of early drug discovery Br. J. Pharmacol. 2010 10.1111/j.1476-5381.2010.01127
3. Holden, A (2008) Detecting and investigating drug-induced adverse events: The international serious adverse event consortium's experience. 2008. [accessed October 17, 2008]. www.fda.gov/cder/livertox/presentations2008/T- Holden2.pdf.
4. N. Kaplowitz Idiosyncratic drug hepatotoxicity Nat. Rev. Drug Discov. 4 2005 489 499 (Pubitemid 40861991)
5. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715 (Pubitemid 39173511)
6. S.I. Makarova Human N-acetyltransferases and drug-induced hepatotoxicity Curr. Drug Metab. 9 2008 538 545 (Pubitemid 352025185)
7. W.M. Lee Drug-induced hepatotoxicity N. Engl. J. Med. 349 2003 474 485 (Pubitemid 36910027)
8. E.A. Gale Lessons from the glitazones: a story of drug development Lancet 357 2001 1870 1875 (Pubitemid 32539124)
9. A.J. Strain, and J.M. Neuberger A bioartificial liver - state of the art Science 295 2002 1005 1009
10. A.R. Steward Changes in the concentration of seven forms of cytochrome P-450 in primary cultures of adult rat hepatocytes Mol. Pharmacol. 27 1985 125 132 (Pubitemid 15162395)
11. J.M. Millis, and J.E. Losanoff Technology insight: liver support systems Nat. Clin. Pract. Gastroenterol. Hepatol. 2 2005 398 405 (Pubitemid 41486092)
12. S.M. Coward Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma Artif. Organs 33 2009 1117 1126
13. R.A. Chamuleau Future of bioartificial liver support World J. Gastrointest. Surg. 1 2009 21 25
14. J.C. Gerlach Lidocaine/monoethylglycinexylidide test, galactose elimination test, and sorbitol elimination test for metabolic assessment of liver cell bioreactors Artif. Organs 34 2010 462 472
15. R. Sharma Three-dimensional culture of human embryonic stem cell derived hepatic endoderm and its role in bioartificial liver construction J. Biomed. Biotechnol. 2010 2010 236147
16. J.J. Xu Cellular imaging predictions of clinical drug-induced liver injury Toxicol. Sci. 105 2008 97 105
17. A. Banas Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes Hepatology 46 2007 219 228 (Pubitemid 47171939)
18. J. Lue Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach Liver Int. 30 2010 913 922
19. J.C. Ruiz Differentiated human adipose-derived stem cells exhibit hepatogenic capability in vitro and in vivo J. Cell Physiol. 225 2010 429 436
20. R. Talens-Visconti Human mesenchymal stem cells from adipose tissue: differentiation into hepatic lineage Toxicol. In Vitro 21 2007 324 329 (Pubitemid 46205076)
21. H. Aurich Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo Gut 58 2009 570 581
22. R. Zemel Expression of liver-specific markers in naive adipose-derived mesenchymal stem cells Liver Int. 29 2009 1326 1337
23. M. Wang Hepatogenesis of adipose-derived stem cells on poly-lactide-co-glycolide scaffolds: in vitro and in vivo studies Tissue Eng. Part C: Methods 16 2010 1041 1050
24. A. Bonora-Centelles Sequential hepatogenic transdifferentiation of adipose tissue-derived stem cells: relevance of different extracellular signaling molecules, transcription factors involved, and expression of new key marker genes Cell Transplant. 18 2009 1319 1340
25. H. Okura Properties of hepatocyte-like cell clusters from human adipose tissue-derived mesenchymal stem cells Tissue Eng. Part C: Methods 16 2010 761 770
26. G.J. Sullivan Generation of functional human hepatic endoderm from human induced pluripotent stem cells Hepatology 51 2010 329 335
27. H. Liu Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes Hepatology 51 2010 1810 1819
28. Z. Song Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells Cell Res. 19 2009 1233 1242
29. K. Si-Tayeb Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells Hepatology 51 2010 297 305
30. S.T. Rashid Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells J. Clin. Invest. 120 2010 3127 3136
31. S. Espejel Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice J. Clin. Invest. 120 2010 3120 3126
32. T. Touboul Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development Hepatology 51 2010 1754 1765
33. Y. Duan Differentiation and characterization of metabolically functioning hepatocytes from human embryonic stem cells Stem Cells 28 2010 674 686
34. M. Ek Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells Biochem. Pharmacol. 74 2007 496 503 (Pubitemid 46970845)
35. T. Soderdahl Glutathione transferases in hepatocyte-like cells derived from human embryonic stem cells Toxicol. In Vitro 21 2007 929 937 (Pubitemid 46628908)
36. G. Brolen Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage J. Biotechnol. 145 2010 284 294
37. J. Cai Directed differentiation of human embryonic stem cells into functional hepatic cells Hepatology 45 2007 1229 1239 (Pubitemid 46775786)
38. H. Basma Differentiation and transplantation of human embryonic stem cell-derived hepatocytes Gastroenterology 136 2009 990 999
39. K. Loya Hepatic differentiation of pluripotent stem cells Biol. Chem. 390 2009 1047 1055
40. S. Agarwal Efficient differentiation of functional hepatocytes from human embryonic stem cells Stem Cells 26 2008 1117 1127
41. D.C. Hay Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling Proc. Natl Acad. Sci. U.S.A. 105 2008 12301 12306
42. H. Baharvand Differentiation of human embryonic stem cells into hepatocytes in 2D and 3D culture systems in vitro Int. J. Dev. Biol. 50 2006 645 652 (Pubitemid 44544754)
43. T. Ishii In vitro hepatic maturation of human embryonic stem cells by using a mesenchymal cell line derived from murine fetal livers Cell Tissue Res. 339 2010 505 512
44. J. Synnergren Transcriptional profiling of human embryonic stem cells differentiating to definitive and primitive endoderm and further toward the hepatic lineage Stem Cells Dev. 19 2010 961 978
45. L.L. Rubin Stem cells and drug discovery: the beginning of a new era? Cell 132 2008 549 552 (Pubitemid 351253700)
46. S. Greenhough Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening Toxicology 278 2010 250 255
47. L.E. Greenbaum From skin cells to hepatocytes: advances in application of iPS cell technology J. Clin. Invest. 120 2010 3102 3105
48. Z. Hannoun The comparison between conditioned media and serum-free media in human embryonic stem cell culture and differentiation Cell Reprogram. 12 2010 133 140
49. H.P. Huang Factors from human embryonic stem cell-derived fibroblast-like cells promote topology-dependent hepatic differentiation in primate embryonic and induced pluripotent stem cells J. Biol. Chem. 285 2010 33510 33519
50. F. Li Hepatoblast-like progenitor cells derived from embryonic stem cells can repopulate livers of mice Gastroenterology 139 2010 2158 2169
51. D.M. Dalgetty Progress and future challenges in stem cell-derived liver technologies Am. J. Physiol. Gastrointest. Liver Physiol. 297 2009 241 248
52. J. Jensen Human embryonic stem cell technologies and drug discovery J. Cell Physiol. 219 2009 513 519
53. P. Sartipy The application of human embryonic stem cell technologies to drug discovery Drug Discov. Today 12 2007 688 699 (Pubitemid 47362783)
54. J. McNeish Embryonic stem cells in drug discovery Nat. Rev. Drug Discov. 3 2004 70 80 (Pubitemid 38088699)
55. S.J. Matthews, and C. McCoy Thalidomide: a review of approved and investigational uses Clin. Ther. 25 2003 342 395 (Pubitemid 36286909)
56. G. Suntharalingam Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 N. Engl. J. Med. 355 2006 1018 1028 (Pubitemid 44343545)
57. A.D. Ebert, and C.N. Svendsen Human stem cells and drug screening: opportunities and challenges Nat. Rev. Drug Discov. 9 2010 367 372
58. S. Asgari Induced pluripotent stem cells: a new era for hepatology J. Hepatol. 53 2010 738 751
59. N. Nakatsuji HLA-haplotype banking and iPS cells Nat. Biotechnol. 26 2008 739 740 (Pubitemid 351961440)
60. C.J. Taylor Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching Lancet 366 2005 2019 2025 (Pubitemid 41773377)
61. G.R. Wilkinson Drug metabolism and variability among patients in drug response N. Engl. J. Med. 352 2005 2211 2221
62. U.A. Meyer Pharmacogenetics - five decades of therapeutic lessons from genetic diversity Nat. Rev. Genet. 5 2004 669 676 (Pubitemid 39150124)
63. M. Quante, and T.C. Wang Stem cells in gastroenterology and hepatology Nat. Rev. Gastroenterol. Hepatol. 6 2009 724 737
64. A.J. Kniazeff Detection of bovine viruses in fetal bovine serum used in cell culture In Vitro 11 1975 400 403
65. N.J. Hewitt Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies Drug Metab. Rev. 39 2007 159 234
66. 2 transport within engineered hepatic devices Biotechnol. Bioeng. 82 2003 12 27 (Pubitemid 36336864)
67. S. Kidambi Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance Proc. Natl Acad. Sci. U.S.A. 106 2009 15714 15719
68. K.M. Stevens Oxygen requirements for liver cells in vitro Nature 206 1965 199
69. Y. Nahmias A novel formulation of oxygen-carrying matrix enhances liver-specific function of cultured hepatocytes FASEB J. 20 2006 2531 2533
70. A. Rotem Oxygen uptake rates in cultured rat hepatocytes Biotechnol. Bioeng. 40 1992 1286 1291
71. A. Rotem Oxygen is a factor determining in vitro tissue assembly: effects on attachment and spreading of hepatocytes Biotechnol. Bioeng. 43 1994 654 660 (Pubitemid 24090712)
72. W.F. McLimans Kinetics of gas diffusion in mammalian cell culture systems (IL theory) Biotechnol. Bioeng. 10 1968 741 763
73. M.D. Jensen Diffusion in tissue cultures on gas-permeable and impermeable supports J. Theor. Biol. 56 1976 443 458
74. E. Sotaniemi Half-life of tolbutamide in patients with chronic respiratory failure Eur. J. Clin. Pharmacol. 4 1971 29 31
75. G.R. Park What changes drug metabolism in critically ill patients? Two preliminary studies in isolated human hepatocytes Anaesthesia 49 1994 188 189
76. C.W. Bryan-Brown Oxygen transport in the critically ill patient Baillire's Clin. Anaesthesiol. 6 1992 25 38
77. P.W. Angus Review article: hypoxia and hepatic drug metabolism - clinical implications Aliment Pharmacol. Ther. 4 1990 213 225 (Pubitemid 20377051)
78. D.P. Jones Drug metabolism and toxicity during hypoxia Drug Metab. Rev. 20 1989 247 260 (Pubitemid 19277700)
79. S. Kaihara Silicon micromachining to tissue engineer branched vascular channels for liver fabrication Tissue Eng. 6 2000 105 117 (Pubitemid 30227167)
80. G. Catapano The effect of oxygen transport resistances on the viability and functions of isolated rat hepatocytes Int. J. Artif. Organs 19 1996 61 71 (Pubitemid 26075735)
81. M. Maringka Preclinical characterization of primary porcine hepatocytes in a clinically relevant flat membrane bioreactor Biomaterials 31 2010 156 172
82. X. Gidrol 2D and 3D cell microarrays in pharmacology Curr. Opin. Pharmacol. 9 2009 664 668
83. F. Pampaloni The third dimension bridges the gap between cell culture and live tissue Nat. Rev. Mol. Cell Biol. 8 2007 839 845 (Pubitemid 47462131)
84. FDA, 2005 FDA (Food and Drug Administration), Center for Drug Evaluation and Research. August, 2005. Guidance for Industry, Impurities in Drug Product Revision. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072861.pdf.
85. C. Xu Human embryonic stem cell-derived cardiomyocytes can be maintained in defined medium without serum Stem Cells Dev. 15 2006 931 941 (Pubitemid 46147863)
86. S. Zhang PuraMatrix: self-assembling peptide nanofiber scaffolds Ma Elisseeff Scaffolding in Tissue Engineering 2005 Tayor & Francis Boca Raton, FL, USA 218 238
87. K. Saha Designing synthetic materials to control stem cell phenotype Curr. Opin Chem. Biol. 11 2007 381 387 (Pubitemid 47302843)
88. S. Zhang Fabrication of novel biomaterials through molecular self-assembly Nat. Biotechnol. 21 2003 1171 1178 (Pubitemid 37186173)
89. S. Giri Telomerase activity and hepatic functions of rat embryonic liver progenitor cell in nanoscaffold-coated model bioreactor Mol. Cell Biochem. 336 2010 137 149
90. G. Mazzoleni Modelling tissues in 3D: the next future of pharmaco-toxicology and food research? Genes Nutr. 4 2009 13 22
91. S. Giri Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages Expert Opin. Drug Metab. Toxicol. 6 2010 895 917
92. U. Fagerholm Prediction of human pharmacokinetics-biliary and intestinal clearance and enterohepatic circulation J. Pharm. Pharmacol. 60 2008 535 542 (Pubitemid 351589043)
93. A. Kern Drug metabolism in hepatocyte sandwich cultures of rats and humans Biochem. Pharmacol. 54 1997 761 772 (Pubitemid 27404677)
94. S. Wilkening Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties Drug Metab. Dispos. 31 2003 1035 1042 (Pubitemid 36975674)
95. J.H. Fruhauf Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells Liver Int. 29 2009 1553 1561
96. C. Patience Infection of human cells by an endogenous retrovirus of pigs Nat. Med. 3 1997 282 286 (Pubitemid 27112924)
97. L.J. van der Laan Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice Nature 407 2000 90 94
98. W. Heneine No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts Lancet 352 1998 695 699 (Pubitemid 28398705)
99. J.H. Ansede An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes Drug Metab. Dispos. 38 2010 276 280
100. B. Swift Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity Drug Metab. Rev. 42 2010 446 471
101. 99mTechnetium-Sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes Pharm. Res. 27 2010 1987 1988
102. B. Swift, and K.L. Brouwer Influence of seeding density and extracellular matrix on bile acid transport and mrp4 expression in sandwich-cultured mouse hepatocytes Mol. Pharm. 7 2010 491 500
103. A.J. Lean, and D.G. Le Couteur Aging biology and geriatric clinical pharmacology Pharmacol. Rev. 56 2004 163 184 (Pubitemid 38720828)
104. Y. Ito Age-related changes in the hepatic microcirculation in mice Exp. Gerontol. 42 2007 789 797 (Pubitemid 47058865)
105. M. Zoli Total and functional hepatic blood flow decrease in parallel with ageing Age Ageing 28 1999 29 33
106. D.G. Le Couteur Hepatic pseudocapillarisation and atherosclerosis in ageing Lancet 359 2002 1612 1615 (Pubitemid 34621132)
107. P.A. Lang Aggravation of viral hepatitis by platelet-derived serotonin Nat. Med. 14 2008 756 761 (Pubitemid 351951519)
108. S. Ijaz Impairment of hepatic microcirculation in fatty liver Microcirculation 10 2003 447 456 (Pubitemid 39004270)
109. J. Gasco State-of-the-art management and monitoring of brain edema and intracranial hypertension in fulminant hepatic failure. A proposed algorithm Acta Neurochir. Suppl. 106 2010 311 314
110. N.R. Fruhauf A bioartificial liver support system using primary hepatocytes: a preclinical study in a new porcine hepatectomy model Surgery 136 2004 47 56 (Pubitemid 38834219)
111. C.B. Frederick, and R.S. Obach Metabolites in safety testing: 'MIST' for the clinical pharmacologist Clin. Pharmacol. Ther. 87 2010 345 350
112. D.A. Smith, and R.S. Obach Metabolites and safety: what are the concerns, and how should we address them? Chem. Res. Toxicol. 19 2006 1570 1579 (Pubitemid 44975120)
113. A. Fura Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery J. Med. Chem. 47 2004 4339 4351 (Pubitemid 39096823)
114. A. Acikgoz Two compartment model of diazepam biotransformation in an organotypical culture of primary human hepatocytes Toxicol. Appl. Pharmacol. 234 2009 179 191
115. W.W. Wang Assessment of a micropatterned hepatocyte co-culture system to generate major human excretory and circulating drug metabolites Drug Metab. Dispos. 38 2010 1900 1905
116. S.C. Gad Active drug metabolites in drug development Curr. Opin. Pharmacol. 3 2003 98 100 (Pubitemid 36131334)
117. S.M. Huang, and R. Temple Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice Clin. Pharmacol. Ther. 84 2008 287 294
118. P. Libby How our growing understanding of inflammation has reshaped the way we think of disease and drug development Clin. Pharmacol. Ther. 87 2010 389 391
119. S.-M. Huang Therapeutic protein-drug interactions and implications for drug development Clin. Pharmacol. Ther. 87 2010 497 503
120. E.T. Morgan Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics Clin. Pharmacol. Ther. 85 2009 434 438
121. V.D. Schmith, and J.F. Foss Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies Clin. Pharmacol. Ther. 87 2010 488 491
122. V. Petrovic Regulation of drug transporters during infection and inflammation Mol. Interv. 7 2007 99 111 (Pubitemid 46683180)
123. R. Taub Liver regeneration: from myth to mechanism Nat. Rev. Mol. Cell Biol. 5 2004 836 847 (Pubitemid 39336277)
124. D.M. Qato Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States JAMA 300 2008 2867 2878
125. N. O'Connor Hepatocellular damage from non-steroidal anti-inflammatory drugs QJM 96 2003 787 791 (Pubitemid 37369293)
126. W. Zou Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system Toxicol. Sci. 108 2009 184 193
127. L. Azzalini Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats Hepatology 51 2010 1567 1576
128. M.J. Kraemer Altered theophylline clearance during an influenza B outbreak Pediatrics 69 1982 476 480 (Pubitemid 12135951)
129. K.A. Slaviero Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy Lancet Oncol. 4 2003 224 232 (Pubitemid 36503320)
130. J.I. Lee CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications Clin. Pharmacokinet. 49 2010 295 310
131. J.J. Feld, and J.H. Hoofnagle Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 436 2005 967 972 (Pubitemid 41191673)
132. J.H. Hoofnagle Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report N. Engl. J. Med. 315 1986 1575 1578 (Pubitemid 17055392)
133. D.A. Katz Defining drug disposition determinants: a pharmacogenetic- pharmacokinetic strategy Nat. Rev. Drug Discov. 7 2008 293 305